Drug intelligence / Profile preview

DX-4012

Development stage: Discontinued
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**DX-4012** is a fully human monoclonal antibody that inhibits **factor XIIa (FXIIa)**, a key component at the crosstalk of the kallikrein-kinin system (KKS) and intrinsic coagulation cascade. Discovered using Dyax's proprietary phage display technology, it demonstrated anti-thrombotic activity in various animal models, supporting its potential in **thromboprophylaxis**. Developed initially by Dyax Corp. (later acquired by Shire/Takeda), the program reached preclinical stages with data presented at the 2015 American Society of Hematology meeting but has since been discontinued.[1][3][5]

Targets

FXIIa (Coagulation Factor XIIa)

Beyond the preview

Go deeper on DX-4012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-4012.

Explore the full profile